Thu, Dec 25, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Investment management group Stenham expands activities in Bermuda and the Caribbean

Monday, October 26, 2009
Opalesque Industry Updates - Stenham has hired Paul Bailey as an exclusive consultant for the region. Mr Bailey comes with an impressive track record of assisting professional advisors and their clients in offshore markets including Bermuda, the Caribbean and the Channel Islands. He spent 10 years with GAM in London and Bermuda and has extensive knowledge of the region and its important decision makers. His remit with Stenham will be to leverage his experience of those markets and develop the firm’s relationships with key professional advisors and their clients.

Harry Wulfsohn, Director and Head of Institutional Business Development commented: ‘Bermuda and the Caribbean have recognised for some time the benefits of Absolute Return Strategies, including alternative investments, as an important tool to improve diversification and reduce volatility. At Stenham, it is fundamental for us to work with experienced people who have a deep local knowledge of their markets and we are delighted to welcome Paul as a consultant. This important development is a significant part of our growth strategy for offshore markets. In all our markets we are committed to our philosophy of wealth preservation and focusing as much on managing risk as delivering returns.’

Paul Bailey commented: ‘I am delighted to be working with Stenham. I have known of the firm for many years and have been particularly impressed with its management team, 20 year track record of capital preservation, and its results against its peers both long term and more recently during the credit crisis. Stenham’s philosophy and approach has been well received in these offshore jurisdictions and I am looking forward to expanding Stenham’s activities.’

***

Stenham is an investment management group providing financial solutions and products to institutions and high net worth private clients. Stenham currently has around US$ 5.4 billion under management, of which US$ 2.5 billion is managed through its multi-manager hedge fund portfolios, whilst US$ 2.9 billion represents the market value of the properties in which Stenham is invested. It operates from a network of global offices including the Channel Islands and the UK, with offices in five other countries around the world.


Be

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its